Migraine Therapeutic Market, By Therapeutics (Pain-relieving Medications and Preventive Medications), By Route of Administration (Oral and Nasal and Injection), and By Geography (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Jan 2023

Code : CMI575

Pages :165

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Migraine Therapeutic Market: Key Developments

In March 2022, AbbVie reported a positive phase 3 progress trial evaluating atogepant (QULIPTA in the U.S.) for the preventive treatment of chronic migraine in adults.

In November 2021, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. collaborated for the commercialization of Rimegepant outside the United States. Rimegepant is commercialized as Nurtec ODT in the U.S., and is indicated for the acute treatment of migraine attacks with/without aura and the preventive treatment of episodic migraine in adults.

In September 2021, the United States Food and Drug Administration (FDA) approved QULIPTA (atogepant) to AbbVie for the prevention of episodic migraine in adults.

In July 2019, Biohaven Pharma Holding Company Ltd. announced the launch of a campaign called 'Demand More' highlighting what patients want and need from an acute treatment of migraine in their own words. It helps in increasing the awareness regarding migraine.